CA3181694A1 - Use of cannabidiol in the treatment of epilepsy - Google Patents
Use of cannabidiol in the treatment of epilepsy Download PDFInfo
- Publication number
- CA3181694A1 CA3181694A1 CA3181694A CA3181694A CA3181694A1 CA 3181694 A1 CA3181694 A1 CA 3181694A1 CA 3181694 A CA3181694 A CA 3181694A CA 3181694 A CA3181694 A CA 3181694A CA 3181694 A1 CA3181694 A1 CA 3181694A1
- Authority
- CA
- Canada
- Prior art keywords
- cbd
- caffeine
- cannabidiol
- day
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009321.7A GB202009321D0 (en) | 2020-06-18 | 2020-06-18 | Use of cannabinoids in the treatment of epilepsy |
| GB2009321.7 | 2020-06-18 | ||
| PCT/GB2021/051520 WO2021255446A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3181694A1 true CA3181694A1 (en) | 2021-12-23 |
Family
ID=71838306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3181694A Pending CA3181694A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230225986A1 (https=) |
| EP (1) | EP4167980B1 (https=) |
| JP (1) | JP2023530500A (https=) |
| KR (1) | KR20230026337A (https=) |
| CN (1) | CN115916168A (https=) |
| AU (1) | AU2021291128A1 (https=) |
| CA (1) | CA3181694A1 (https=) |
| GB (2) | GB202009321D0 (https=) |
| MX (1) | MX2022016038A (https=) |
| TW (1) | TW202214217A (https=) |
| WO (1) | WO2021255446A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2024300440A1 (en) * | 2023-07-25 | 2026-03-12 | Algorae Pharmaceuticals Ltd | Compositions and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015308546A1 (en) * | 2014-08-25 | 2017-04-13 | Clk Consult V/ Carsten Leonhard Knudsen | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US20180360771A1 (en) * | 2017-06-14 | 2018-12-20 | Yury Leon Shmerlis | Cannabidiol chewing gum |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN109985042A (zh) * | 2017-12-29 | 2019-07-09 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用 |
| US20200172841A1 (en) * | 2018-12-04 | 2020-06-04 | Donald F. Wilkes | Alcohol-free wine beverage |
-
2020
- 2020-06-18 GB GBGB2009321.7A patent/GB202009321D0/en not_active Ceased
-
2021
- 2021-06-16 JP JP2022578719A patent/JP2023530500A/ja active Pending
- 2021-06-16 MX MX2022016038A patent/MX2022016038A/es unknown
- 2021-06-16 US US18/002,437 patent/US20230225986A1/en active Pending
- 2021-06-16 AU AU2021291128A patent/AU2021291128A1/en active Pending
- 2021-06-16 KR KR1020227044124A patent/KR20230026337A/ko active Pending
- 2021-06-16 CN CN202180042463.2A patent/CN115916168A/zh active Pending
- 2021-06-16 WO PCT/GB2021/051520 patent/WO2021255446A1/en not_active Ceased
- 2021-06-16 CA CA3181694A patent/CA3181694A1/en active Pending
- 2021-06-16 EP EP21736654.1A patent/EP4167980B1/en active Active
- 2021-06-17 TW TW110122055A patent/TW202214217A/zh unknown
- 2021-06-17 GB GB2108690.5A patent/GB2598187A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4167980A1 (en) | 2023-04-26 |
| AU2021291128A1 (en) | 2022-12-01 |
| KR20230026337A (ko) | 2023-02-24 |
| CN115916168A (zh) | 2023-04-04 |
| GB202009321D0 (en) | 2020-08-05 |
| TW202214217A (zh) | 2022-04-16 |
| WO2021255446A1 (en) | 2021-12-23 |
| MX2022016038A (es) | 2023-02-02 |
| GB202108690D0 (en) | 2021-08-04 |
| US20230225986A1 (en) | 2023-07-20 |
| GB2598187A (en) | 2022-02-23 |
| JP2023530500A (ja) | 2023-07-18 |
| EP4167980B1 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6014083B2 (ja) | 眠気覚まし用組成物 | |
| JP6014731B2 (ja) | 褐藻類抽出物を有効成分とするｇａｂａａ−ベンゾジアゼピン受容体活性を有する睡眠誘導及び改善用組成物 | |
| CN102088970B (zh) | 用含槲皮素的组合物在制备改善肾功能的药物中的应用 | |
| EP4167980B1 (en) | Use of cannabidiol in the treatment of childhood-onset epilepsy in patients who are concurrently taking caffeine | |
| US11925645B2 (en) | Enhanced caffeinated beverage composition | |
| US20040171624A1 (en) | Pharmaceutical composition for treating mood disorders | |
| US8518458B2 (en) | Tea-derived compositions and methods of using same for cardiovascular health | |
| JP2003286167A (ja) | エピガロカテキンガレートを含有するアセチルコリンエステラーゼ阻害剤、薬学的製剤及び食品 | |
| UA129270C2 (uk) | Композиція тразодону педіатричного призначення | |
| JP2017534578A (ja) | ジペノサイド（ｇｙｐｅｎｏｓｉｄｅ）ｌｘｘｖを含む、子宮頸癌の予防又は治療用組成物 | |
| KR101864384B1 (ko) | 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법 | |
| US11173143B2 (en) | Composition for decreasing serum uric acid level | |
| US11439603B2 (en) | Compositions for ameliorating, preventing or treating somnipathy including phloroglucinol as active ingredient and compositions for suppressing intolerance to or alleviating side effects of agonist at benzodiazepine binding site of GABA-A receptor including phloroglucinol as active ingredient | |
| US20090214682A1 (en) | Composition and methods for weight loss in a subject | |
| KR101564059B1 (ko) | 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 | |
| KR101841654B1 (ko) | 콜린 알포세레이트를 유효성분으로 하는 신경병증성 통증의 치료, 개선 또는 예방용 조성물 및 방법 | |
| JP2009149545A (ja) | 内服液剤 | |
| AU2018101586A4 (en) | Uses of polydatin | |
| JP2006335752A (ja) | アルドース還元酵素阻害剤 | |
| JP7754447B2 (ja) | ストレスを軽減するための組成物 | |
| JPH0551320A (ja) | 肝機能改善剤 | |
| Abdelkawy et al. | Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using midazolam as CYP3A4 enzyme probe | |
| KR20250176608A (ko) | TPCK(tosyl phenylalanyl chloromethyl ketone)을 유효성분으로 포함하는 치주질환 예방, 개선 또는 치료용 약학적 조성물 | |
| Angelopoulos et al. | Α Randomized, Placebo-Controlled Trial to assess the Efficacy and Safety of a Novel Nutraceutical Combination of Monacolin K and Bergamot extract in subjects with Mild to Moderate Hypercholesterolemia | |
| KR20200052043A (ko) | 애기 기린초 추출물을 유효성분으로 포함하는 인지능력 개선, 및 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20250227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250320 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250612 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250612 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250616 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250619 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250822 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250822 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250822 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |